Crohn's Drug Gives MediTech Big Break (China)
This article was originally published in PharmAsia News
Executive Summary
Hutchison China MediTech's experimental drug HMPL-004 for treating Crohn's disease has performed well in phase-II clinical trials and looks promising for eventual approval. Current data shows HMPL-004 at least as effective as current available therapies. The drug is based on a compound used in traditional Chinese, and it is targeting treatment of ulcerative colitis and Crohn's disease. Both diseases are autoimmune diseases of the upper and lower intestines, and modern pharmaceutical medicine can help about 60 percent of patients. The company is owned by Hong Kong-based Hutchison. (Click here for more
|
Hutchison China MediTech's experimental drug HMPL-004 for treating Crohn's disease has performed well in phase-II clinical trials and looks promising for eventual approval. Current data shows HMPL-004 at least as effective as current available therapies. The drug is based on a compound used in traditional Chinese, and it is targeting treatment of ulcerative colitis and Crohn's disease. Both diseases are autoimmune diseases of the upper and lower intestines, and modern pharmaceutical medicine can help about 60 percent of patients. The company is owned by Hong Kong-based Hutchison. (Click here for more )
"Crohn's Drug Gives MediTech Big
Break"
|